BioAnalytica-GenoType SA is a spin-off company, offering state-of-the-art cytogenetic and molecular genetic services of outstanding quality to health professionals, biomedical researchers and top multinational pharmaceutical enterprises. The company was founded by BioAnalytica SA, a leading provider of molecular analysis technology infrastructure and consumables and the researcher Dr.Georgia Bardi. The company performs clinical genetic analysis services, based on established international guidelines and also, provides genetic testing services to support clinical trials, research, validation of new molecular assays and drug development. The scientific team carries out: 1) applied genetic research to identify novel genetic markers in Hematology/Oncology and incorporate their analysis in genomic medicine, and 2) routine molecular microbiology testing for infectious diseases.
BioAnalytica-GenoType SA is recognized as a leader in providing quality laboratory services and has earned a solid reputation based on the knowledge, integrity and professionalism of its staff. It has been the first genetic laboratory in Greece and among few genetic labs in Europe that, since 2007, met the international internal and external quality standards to get ISO 15189 accreditation.
Based on the expertise in cancer genetics/cytogenetics and molecular microbiology as well as on the engagement in both cancer diagnostics and research, the current target of BioAnalytica-GenoType SA is to expand abroad, mostly through strategic collaborations with companies that will augment the sales network internationally.
The laboratory of BioAnalytica-GenoType SA is well-designed with modern facilities and equipment, and with dedicated staff. It is located centrally in Athens and can serve quickly and easily Europe, Middle East, Balkan and Russia.
General Hospitals and Clinics for Oncology, Haematology, Gynaecology, Infectious diseases, Intensive Care Units, Microbiology, Cardiology, Pathology, Urology, Orthopaedic, Paediatric, specialties for diagnostic reasons.
Diagnostic network centres & academic groups
Medical Insurance Organizations
Pharmaceutical companies performing interventional and marketing trials or seeking collaborations on pharmacogenomic projects and drug development
CROs in need of genetic services for clinical purposes, including companion diagnostics as well as for clinical trials in haematology-oncology and infectious diseases
Biotechechnology companies/ diagnostic kit manufacturers for validation of new molecular assays
Technologies / Services offered or sought
World-class expertise in cancer cytogenetics complimented by all state-of-the art molecular genetic methodologies for both clinical and research services in Hematology-Oncology.
Top quality genetic laboratory services, adherence to the European legislation, bioethics and personal data handling, documented by ISO 15189 certification, as well as successful participation in External Quality Assessment Inter-laboratory European Schemes.
Karyotype/high resolution Karyotype
Fluorescent in situ hybridization
Differential ‘painting’ of one or more chromosomes, or of the entire genome (multicolor-FISH)
Differential detection of chromosome bands of one or more chromosomes (M-Band)
Analysis of mitotic and interphase nuclei with FISH
With probes for repeating DNA sequences (centromeric/telomeric)
With probes specific for chromosome or gene loci
Genomic analysis with comparative genome hybridization (CGH)